Works Cited

1. Drewes AM, Jensen RD, Neilsen LM, et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives.Br J Clin Pharmacol. 2012;75(1):60-78.

2. Institute of Medicine.Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: National Academies Press; 2011.

3. Fudin J, Atkinson TJ. Opioid prescribing levels off, but is less really more?Pain Med. 2014;15(2):184-187.

4. Jamison RN, Scanlan E, Matthews ML, Juircik DC, Ross EL. Attitudes of primary care practitioners in managing chronic pain patients prescribed opioids for pain: a prospective longitudinal controlled trial.Pain Med. 2016;17(1):99-113.

5. Twillman B, American Academy of Pain Management. Academy's Response: CDC's Guideline for Prescribing Opioids for Chronic Pain. Available at http://blog.aapainmanage.org/academys-response-center-disease-controls-guideline-prescribing-opioids-chronic-pain. Last accessed May 17, 2017.

6. Fudin J, Cleary JP, Schatman ME. The MEDD myth: the impact of pseudoscience on pain research and prescribing-guideline development.J Pain Res. 2016;9:153-156.

7. Schatman ME. The American chronic pain crisis and the media: about time to get it right?J Pain Res. 2015;8:885-887.

8. Nadeau SE. Opioids for chronic noncancer pain: to prescribe or not to prescribe—what is the question?Neurology. 2015;85(7): 646-651.

9. Wallace LS, Keenum AJ, AbdurRaqeeb O, Miser WF, Wexler RK. Terminology matters: patient understanding of "opioids" and "narcotics."Pain Pract. 2013;13(2):104-108.

10. Oliver J, Coggins C, Compton P, et al. American Society for Pain Management Nursing position statement: pain management in patients with substance use disorders.Pain Manag Nurs. 2012;13(3):169-183.

11. McPherson ML. Opioids: fears, myths, and misconceptions.PainView. 2011;7:16-18.

12. Sloan PA, Davis MP, Gamier P. ER/LA opioid REMS supplement.J Opioid Manag.2014;10(7):1-48.

13. Yaksh TL, Woller SA, Ramachandran R, Sorkin LS. The search for novel analgesics: targets and mechanisms.F1000Prime Reports. 2015;7:56.

14. Woolf CJ. What is this thing called pain?J Clin Invest. 2010;120(11):3742-3744.

15. National Comprehensive Cancer Network. Adult Cancer Pain, 2017. Available at https://www.nccn.org/professionals/physician_gls/PDF/pain.pdf. Last accessed May 17, 2017.

16. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology.Pain Physician. 2008;11(2 Suppl):S133-S153.

17. Reichling DB, Levine JD. Critical role of nociceptor plasticity in chronic pain.Trends Neurosci. 2009;32(12):611-618.

18. Buckenmaier CC, Gallagher RM, Cahaba A, et al. War on pain: new strategies in pain management for military personnel and veterans.Federal Practitioner. 2011;6:1-16.

19. Tennant F. Why oral opioids may not be effective in a subset of chronic pain patients.Postgrad Med. 2016;128(1):18-22.

20. American Academy of Pain Medicine. Use of Opioids for the Treatment of Chronic Pain. Available at http://www.painmed.org/files/use-of-opioids-for-the-treatment-of-chronic-pain.pdf. Last accessed May 17, 2017.

21. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000–2014.MMWR. 2016;64(50-51):1378-1382.

22. Atkinson TJ, Schatman ME, Fudin J. The damage done by the war on opioids: the pendulum has swung too far.J Pain Res. 2014;7:265-268.

23. Webster LR. Pain and suicide: the other side of the opioid story.Pain Med. 2014;15(3):345-346.

24. Ziegler SJ. Patient abandonment in the name of opioid safety.Pain Med. 2013;14(3):323-324.

25. Leavitt SB. Another Book About Pain, Only Much Better. Available at http://updates.pain-topics.org/2014/01/another-book-about-pain-only-much-better.html?pfstyle=wp. Accessed May 4, 2016.

26. National Center for Health Statistics. NCHS Data on Drug-Poisoning Deaths. Available at https://www.cdc.gov/nchs/data/factsheets/factsheet_drug_poisoning.htm. Last accessed May 17, 2017.

27. U.S. Drug Enforcement Administration. Pharmacy Diversion Awareness Conference, Available at https://www.deadiversion.usdoj.gov/mtgs/pharm_awareness/conf_2016/march_2016/index.html. Last accessed May 17, 2017.

28. Centers for Disease Control and Prevention. Opioid Data Analysis: Categories of Opioids. Available at http://www.cdc.gov/drugoverdose/data/analysis.html. Last accessed May 17, 2017.

29. U.S. Drug Enforcement Administration. National Forensic Laboratory Information System Special Report: Opiates and Related Drugs Reported in NFLIS, 2009–Available at https://www.deadiversion.usdoj.gov/nflis/spec_rpt_opioids_2014.pdf. Last accessed May 17, 2017.

30. Chou R, Deyo R, Devine B, et al.The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain. Rockville, MD: Agency for Healthcare Research and Quality; 2014.

31. U.S. Drug Enforcement Administration. 2015 National Drug Threat Assessment Summary. Available at https://www.dea.gov/docs/2015%20NDTA%20Report.pdf. Last accessed May 17, 2017.

32. Larochelle MR, Zhang F, Ross-Degnan D, Wharam JF. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.JAMA Intern Med. 2015;175(6):978-987.

33. Coplan PM, Chilcoat HD, Butler SF, et al. The effect of an abuse-deterrent opioid formulation on opioid abuse-related outcomes in the postmarketing setting.Clin Pharmacol Ther. 2016;100(3):275-286.

34. Jones CM, Lurie PG, Throckmorton DC. Effect of U.S. Drug Enforcement Administration's rescheduling of hydrocodone combination analgesic products on opioid analgesic prescribing.JAMA Intern Med. 2016;176(3):399-402.

35. Long D. The U.S. Pharmaceutical Trends, Issues, and Outlook. Available at http://www.imshealth.com/files/web/United%20States/US%20Files/Trends_Issues_Forecasts.pdf. Last accessed May 17, 2017.

36. U.S. Drug Enforcement Administration, Office of Diversion Control. National Forensic Laboratory Information System Special Report: Benzodiazepines Reported in NFLIS, 2009–Available at https://www.deadiversion.usdoj.gov/nflis/NFLIS-SR-Benzos.pdf. Last accessed May 17, 2017.

37. Fudin J.The Hydrocodone Question. Available at http://drugtopics.modernmedicine.com/drug-topics/content/tags/hydrocodone/hydrocodone-question. Last accessed May 17, 2017.

38. Breivik H, Stubhaug A. Burden of disease is often aggravated by opioid treatment of chronic pain patients: etiology and prevention.Pain. 2014;155(12):2441-2443.

39. Häuser W, Petzke F, Radbruch L, Tölle TR. The opioid epidemic and the long-term opioid therapy for chronic noncancer pain revisited: a transatlantic perspective.Pain Manag. 2016;6(3):249-263.

40. Marschall U, L'hoest H, Radbruch L, Häuser W. Long-term opioid therapy for chronic non-cancer pain in Germany.Eur J Pain. 2016;20(5):767-776.

41. Muhuri PK, Gfroerer J, Davies MC. Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States. Available at https://www.samhsa.gov/data/sites/default/files/DR006/DR006/nonmedical-pain-reliever-use-2013.htm. Last accessed May 17, 2017.

42. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016.MMWR. 2016;315(15):1624-1645.

43. American Academy of Pain Medicine. Comments to the CDC on the Proposed 2016 Guideline for Prescribing Opioids for Chronic Pain. Available at http://www.painmed.org/files/aapm-letter-to-cdc-proposed-2016-guidelines-for-prescibing.pdf. Last accessed May 17, 2017.

44. Häuser W, Tölle TR. Meta-analyses of pain studies: what we have learned.Best Pract Res Clin Rheumatol. 2015;29(1):131-146.

45. Watson CPN. Opioids in chronic noncancer pain: more faces from the crowd.Pain Res Manag. 2012;17(4):263-275.

46. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain.N Engl J Med. 2003;348(13):1223-1232.

47. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality.Pain Med. 2016;17(1):85-98.

48. Chen LH, Hedegaard H, Warner M, Centers for Disease Control and Prevention. Drug-Poisoning Deaths Involving Opioid Analgesics: United States, 1999–Available at https://www.cdc.gov/nchs/products/databriefs/db166.htm. Last accessed May 17, 2017.

49. Atkinson TJ, Fudin J, Pandula A, Mirza M. Medication pain management in the elderly: unique and underutilized analgesic treatment options.Clin Ther. 2013;35(11):1669-1689.

50. Lipman A, Webster L. The economic impact of opioid use in the management of chronic nonmalignant pain.J Manag Care Spec Pharm. 2015;21(10):891-899.

51. Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines.Am J Prev Med. 2015;49(4):493-501.

52. Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain.Arch Intern Med. 2011;171(7):686-691.

53. Jones CM, Paulozzi MD, Mack KA. Alcohol involvement in opioid pain reliever and Benzodiazepine drug abuse-related emergency department visits and drug-related deaths—United States, 2010.MMWR. 2014;63(40):881-885.

54. Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related overdose deaths in the United States.Pain Med. 2011;12(Suppl 2):S26-S35.

56. Webster L. The pain epidemic versus the opioid crisis.P T. 2016;41(2):107-115.

57. Ciccone TG, Kean N. Responses and criticisms over new CDC opioid prescribing guidelines.Pract Pain Manag. 2016;16.

58. Carr DB. NPS versus CDC: Scylla, Charybdis and the "number needed to [under-] treat."Pain Medicine. 2016;17:999-1000.

59. Tennant F. Don't flinch from prescribing pain medications!Pract Pain Manag.2016;16(3).

60. Webster L, Pains Project. Change Through The Painful Truth: A Book and TV Documentary. Available at http://www.painsproject.org/change-painful-truth-book-tv-documentary. Last accessed May 17, 2017.

61. Trang T, Al-Hasani R, Salvemini D, Salter MW, Gutstein H, Cahill CM. Pain and poppies: the good, the bad, and the ugly of opioid analgesics.J Neurosci. 2015;35(41):13879-13888.

62. Manchikanti L, Abdi S, Atluri S, et al. An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: guidance and recommendations.Pain Physician. 2013;16(2 Suppl):S49-S283.

63. Collen M. Prescribing cannabis for harm reduction.Harm Reduct J. 2012;9:1.

64. Kennedy J, Roll JM, Schraudner T, Murphy S, McPherson S. Prevalence of persistent pain in the U.S. adult population: new data from the 2010 National Health Interview Survey.J Pain. 2014;15(10):979-984.

65. Manchikanti L, Singh V, Datta S, Cohen SP, Hirsch JA. Comprehensive review of epidemiology, scope, and impact of spinal pain.Pain Physician. 2009;12(4):E35-E70.

66. Simons L, Elman I, Borsook D. Psychological processing in chronic pain: a neural systems approach.Neurosci Biobehav Rev. 2014;39:61-78.

67. O'Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.Pharmacoeconomics. 2009;27(2):95-112.

68. Fredheim OM, Kaasa S, Fayers P, Saltnes T, Jordhøy M, Bortchgrevink PC. Chronic non-malignant pain patients report as poor health-related quality of life as palliative cancer patients.Acta Anaesthesiol Scand. 2008;52(1):143-148.

69. Tennant F. The physiologic effects of pain on the endocrine system.Pain Ther. 2013;2(2):75-86.

70. Torrance N, Elliott AM, Lee AJ, Smith BH. Severe chronic pain is associated with increased 10-year mortality: a cohort record linkage study.Eur J Pain. 2010;14(4):380-386.

71. Jackman RP, Purvis JM, Mallett BS. Chronic nonmalignant pain in primary care.Am Fam Physician. 2008;78(10):1155-1162.

72. Nicholson B. Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain.Pain Pract. 2009;9(1): 71-81.

73. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions.Mayo Clin Proc. 2009;84(7):593-601.

74. Juurlink DN, Hermann N, Szalai JP, Kopp A, Redelmeier DA. Medical illness and the risk of suicide in the elderly.Arch Intern Med. 2004;164(11):1179-1184.

75. Asmundson GJG, Katz J. Understanding the co-occurrence of anxiety disorders and chronic pain: state-of-the-art.Depress Anxiety. 2009;26(10):888-901.

76. Elman I, Borsook D, Volkow ND. Pain and suicidality: insights from reward and addiction neuroscience.Prog Neurobiol. 2013;109: 1-27.

77. Practical Pain Management. Suicide and Suffering In the Elderly: We Must Do Better. Available at https://www.practicalpainmanagement.com/pain/other/co-morbidities/suicide-suffering-elderly-we-must-do-better. Last accessed May 17, 2017.

78. Alford DP, German JS, Samet JH, Cheng DM, Lloyd-Travaglini CA, Saitz R. Primary care patients with drug use report chronic pain and self-medicate with alcohol and other drugs.J Gen Intern Med. 2016;31(5):486-491.

79. Ji RR, Xu ZZ, Gao YJ. Emerging targets in neuroinflammation-driven chronic pain.Nat Rev Drug Discov. 2014;13(7):533-548.

80. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity.J Pain. 2009;10(9):895-926.

81. Danese A, Pariante CM, Caspi A, Taylor A, Poulton R. Childhood maltreatment predicts adult inflammation in a life-course study.Proc Natl Acad Sci USA. 2007;104(4):1319-1324.

82. Boakye PA, Olechowski C, Rashiq S, et al. A critical review of neurobiological factors involved in the interactions between chronic pain, depression, and sleep disruption.Clin J Pain. 2016;32(4):327-336.

83. Walker AK, Kavelaars A, Heijnen CJ, Dantzer R. Neuroinflammation and comorbidity of pain and depression.Pharmacol Rev. 2014;66(1):80-101.

84. Vlaeyen JWS. Psychological mechanisms. Presented at: The Ninth Conference of the European (Pain Federation EFIC); Vienna, Austria; September 2, 2015.

85. Peppin JF, Cheatle MD, Kirsh KL, McCarberg BH. The complexity model: a novel approach to improve chronic pain care.Pain Med. 2015;16(4):653-666.

86. Martel MO, Jamison RN, Wasan AD, Edwards RR. The association between catastrophizing and craving in patients with chronic pain prescribed opioid therapy: a preliminary analysis.Pain Med. 2014;15(10):1757-1764.

87. Bigos SJ, Battie MC, Spengler DM, et al. A prospective study of work perceptions and psychosocial factors affecting the report of back injury.Spine. 1991;16(1):1-6.

88. Williams RA, Pruitt SD, Doctor JN, et al. The contribution of job satisfaction to the transition from acute to chronic low back pain.Arch Phys Med Rehabil. 1998;79(4):366-373.

89. Evers AW, Kraaimaat FW, Geenen R, Jacobs JW, Bijlsma JW. Pain coping and social support as predictors of long-term functional disability and pain in early rheumatoid arthritis.Behav Res Ther. 2003;41(11):1295-1310.

90. Dunbar SA, Katz NP. Chronic opioid therapy for non-malignant pain in patients with a history of substance abuse: report of 20 cases.J Pain Symptom Manage. 1996;11(3):163-171.

91. Macfarlane GJ. What do epidemiological studies tell us about lifestyle and chronic pain? Presented at: The Ninth Conference of the European (Pain Federation EFIC); Vienna, Austria; September 2, 2015.

92. Means-Christensen AJ, Roy-Byrne PP, Sherbourne CD, Craske MG, Stein MB. Relationships among pain, anxiety, and depression in primary care.Depress Anxiety. 2008;25(7):593-600.

93. Okifujo A, Hare BD. Do sleep disorders contribute to pain sensitivity?Curr Rheumatol Rep. 2011;13(6):528-534.

94. Rashiq S, Dick BD. Factors associated with chronic noncancer pain in the Canadian population.Pain Res Manag. 2009;14(6): 454-460.

95. Scherer M, Hansen H, Gensichen J, et al. Association between multimorbidity patterns and chronic pain in elderly primary care patients: a cross-sectional observational study.BMC Fam Pract. 2016;17:68.

96. Buckalew N, Haut MW, Aizenstein H, et al. Differences in brain structure and function in older adults with self-reported disabling and nondisabling chronic low back pain.Pain Med. 2010;11(8):1183-1197.

97. Jacobs JV, Henry SM, Nagle KJ. Low back pain associates with altered activity of the cerebral cortex prior to arm movements that require postural adjustment.Clin Neurophysiol. 2010;121(3):431-440.

98. Aldington D. What is the level of evidence? Indications and limitations. Presented at: The Ninth Conference of the European Pain Federation (Pain Federation EFIC); Vienna, Austria; September 2, 2015.

99. Cregg R, Russo G, Gubbay A, Branford R, Sato H. Pharmacogenetics of analgesic drugs.Br J Pain. 2013;7(4):189-208.

100. Schatman ME, Webster LR. The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability.J Pain Res. 2015;8:153-158.

101. National Pain Strategy. A Comprehensive Population Health-Level Strategy for Pain. Available at https://iprcc.nih.gov/docs/HHSNational_Pain_Strategy.pdf. Last accessed May 17, 2017.

102. University of Wisconsin School of Medicine and Public Health, Pain and Policy Studies Group. Achieving Balance in State Pain Policy: A Progress Report Card (CY 2013). Available at http://www.painpolicy.wisc.edu/sites/www.painpolicy.wisc.edu/files/prc2013.pdf. Last accessed May 17, 2017.

103. Prommer EE. Pharmacological management of cancer-related pain.Cancer Control. 2015;22(4):412-425.

104. Chong WS, Johnson DS. Update on Opioid Pharmacology Anaesthesia: Tutorial of the Week. Available at http://www.aagbi.org/sites/default/files/277%20Update%20on%20Opioid%20Pharmacology%20.pdf. Last accessed May 17, 2017.

105. Yaksh TL, Wallace MS. Opioids, analgesia, and pain management. In: Brunton LL, Chabner BA, Knollmann BC (eds).Goodman and Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York, NY: McGraw-Hill; 2017: 481-525.

106. Pasternak GW. Opioid pharmacotherapy: from receptor to bedside. In: Inturrisi CE, Nicholson B, Pasternak GW (eds).Dual Opioid Therapy. London: The Royal Society of Medicine Press Limited; 2009.

107. Ghelardini C, Di Cesare Mannelli L, Bianchi E. The pharmacological basis of opioids.Clin Cases Miner Bone Metab. 2015;12(3):219-221.

108. McDonald J, Lambert DG. Opioid receptors.Continuing Education in Anaesthesia, Critical Care & Pain. 2005;5(1):22-27.

109. Toll L, Caló G, Cox BM, IUPHAR/BPS Guide to Pharmacology. Opioid Receptors. Available at http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=50. Last accessed May 17, 2017.

110. McKeen MJ, Quraishi SA. Clinical review of intravenous opioids in acute care.J Anesthiol Clin Sci. 2013;2:1-11.

111. Sprouse-Blum AS, Smith G, Sugai D, Parsa FD. Understanding endorphins and their importance in pain management.Hawaii Med J. 2010;69(3):70-71.

112. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG. Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile.Br J Anaesth. 2009;103(1):38-49.

113. Lesniak A, Lipkowski AW. Opioid peptides in peripheral pain control.Acta Neurobiol Exp. 2011;71(1):129-138.

114. Yaksh TL. Pharmacology and mechanisms of opioid analgesic activity.Acta Anaesthesiol Scand. 1997;41(1 Pt 2):94-111.

115. Vallejo R, Barkin RL, Wang VC. Pharmacology of opioids in the treatment of chronic pain syndromes.Pain Physician. 2011;14(4):E343-E360.

116. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin.JAMA. 2005;293(24):3043-3052.

117. Smith HS. Opioids and neuropathic pain.Pain Physician. 2012;15(3 Suppl):ES93-ES110.

118. Sehgal N, Smith H, Manchikanti L. Peripherally acting opioids and clinical implications for pain control.Pain Physician. 2011;14(3):249-258.

119. Haeseler G, Foadi N, Ahrens J, Dengler R, Hecker H, Leuwer M. Tramadol, fentanyl and sufentanil but not morphine block voltage-operated sodium channels.Pain. 2006;126(1-3):234-244.

120. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression.Anesthesiology. 2010;112(1):226-238.

121. Colameco S. Opioid-Induced Sexual Dysfunction: Causes, Diagnosis, and Treatment. Available at http://www.thblack.com/links/RSD/Colameco-Opioids-SexDysfunction.pdf. Last accessed May 17, 2017.

122. U. S. Department of Justice. Drugs of Abuse, 2015 Edition. Available at https://www.dea.gov/pr/multimedia-library/publications/drug_of_abuse.pdf. Last accessed May 17, 2017.

123. National Cancer Institute. Cancer Pain. Available at https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq. Last accessed May 17, 2017.

124. Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions.Exp Clin Psychopharmacol.2008;16(5):405-416.

125. Corbett AD, Henderson G, McKnight AT, Paterson SJ. 75 years of opioid research: the exciting but vain quest for the Holy Grail.Br J Pharmacol. 2006;147(Suppl 1):S153-S162.

126. Felden L, Walter C, Harder S, et al. Comparative clinical effects of hydromorphone and morphine: a meta-analysis.Br J Anaesth. 2011;107(3):319-328.

127. Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients.Support Care Cancer. 2001;9(2):84-96.

128. Amabile CM, Bowman BJ. Overview of oral modified-release opioid products for the management of chronic pain.Ann Pharmacother.2006;40(7-8):1327-1335.

129. Craig DS. Oxymorphone extended-release tablets (Opana ER) for the management of chronic pain.P T. 2010;35(6):324-329, 357.

130. Overholser BR, Foster DR. Opioid pharmacokinetic drug-drug interactions.Am J Manag Care. 2011;17(Suppl 11):S276-S287.

131. U.S. Department of Veterans Affairs. Clinical Practice Guideline for Management of Opioid Therapy (OT) for Chronic Pain. Available at https://www.healthquality.va.gov/guidelines/Pain/cot. Last accessed May 17, 2017.

132. U.S. Government Accountability Office. Report to Congressional Requesters: OxyContin Abuse and Diversion and Efforts to Address the Problem. Available at http://www.gao.gov/new.items/d04110.pdf. Last accessed May 17, 2017.

133. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: partI—evidence assessment.Pain Physician. 2012;15(3 Suppl):S1-S65.

134. Prommer E. Oxymorphone: a review.Support Care Cancer. 2006;14(2):109-115.

135. Pergolizzi JV, Raffa RB, Gould E. Considerations on the use of oxymorphone in geriatric patients.Expert Opin Drug Saf. 2009;8(5):603-613.

136. Homsi J, Walsh D, Nelson KA. Important drugs for cough in advanced cancer.Support Care Cancer.2001;9(8):565-574.

137. Gould HJ, Paul D. Critical appraisal of extended-release hydrocodone for chronic pain: patient considerations.Ther Clin Risk Manag. 2015;11:1635-1640.

138. Krantz MJ, Mehler PS. Treating opioid dependence: growing implications for primary care.Arch Intern Med. 2004;164(3):277-288.

139. Prommer E. Levorphanol: the forgotten opioid.Support Care Cancer. 2007;15(3):259-264.

140. Loitman JE. Levorphanol #240.J Palliat Med. 2011;14(7):875-886.

141. McNulty J. Can levorphanol be used like methadone for intractable refractory pain?J Palliat Med. 2007;10(2):293-296.

142. Fudin J. Unique Levorphanol Dodges Move from Forgotten to Vanished. Available at http://paindr.com/unique-levorphanol-dodges-move-from-forgotten-to-vanished. Last accessed May 17, 2017.

143. Bornemann-Cimenti H, Wejbora M, Szilagyi IS, Sandner-Kiesling A. Fentanyl for the treatment of tumor-related breakthrough pain.Dtsch Arztebl Int. 2013;110(16):271-277.

144. Geppetti P, Benemei S. Pain treatment with opioids: achieving the minimal effective and the minimal interacting dose.Clin Drug Investig. 2009;29(Suppl 1):3-16.

145. Leppert W. CYP2D6 in the metabolism of opioids for mild to moderate pain.Pharmacology. 2011;87(5-6):274-285.

146. Tzschentke T, Christoph T, Kögel B, et al. (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.J Pharmacol Exp Ther. 2007;323(1):265-276.

147. Afilalo M, Etropolski M, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo-and active-controlled phase III study.Clin Drug Invest. 2010;30(8):489-505.

148. Ashworth J, Kuperwasser B, Etropolski M, et al. Assessment of opioid withdrawal in patients treated with tapentadol prolonged release during an open-label extension study. Presented at: The Osteoarthritis Research Society International (OARSI) 2010 World Congress on Osteoarthritis; September 23-26, 2010; Brussels, Belgium.

149. Kulkantrakorn K. Emerging concepts and treatment in neuropathic pain.Neurology Asia. 2012;17(4):265-271.

150. Sánchez del Águila MJ, Schenk M, Kern KU, Drost T, Steingerwald I. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.Clin Ther.2015;37(1):94-113.

151. U.S. Food and Drug Administration. Drug Approval Package: Butrans (Buprenorphine) Transdermal System for Transdermal Administration (5 mcg/hour, 10 mcg/hour, and 20 mcg/hour). Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021306_butrans_toc.cfm. Last accessed May 17, 2017.

152. Finn P, Wilcock K. Levo-alpha acetyl methadol (LAAM): its advantages and drawbacks.J Subst Abuse Treat. 1997;14(6):559-564.

153. Davids E, Gastpar M. Buprenorphine in the treatment of opioid dependence.Eur Neuropsychopharmacol. 2004;14(3):209-216.

154. Woolf CJ, Hashmi M. Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids.Curr Opin Investig Drugs. 2004;5(1):61-66.

155. Harris LS, May EL. Historical introduction and review of chemistry.Drug Alcohol Depend. 1985;14(3-4):227-232.

156. Trescot A, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) guidelines.Pain Physician.2009;11(2 suppl):S5-S62.

157. Chou R, Fanciullo G, Fine P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer patients.J Pain. 2009;10(2):113-130.

158. Mitra A, Kotz CM, Kim EM, et al. Effects of butorphanol on feeding and neuropeptide Y in the rat.Pharmacol Biochem Behav. 2012;100(3):575-580.

159. Zucker JR, Neuenfeldt T, Freund PR. Respiratory effects of nalbuphine and butorphanol in anesthetized patients.Anesth Analg. 1987;66(9):879-881.

160. Zola EM, McLeod DC. Comparative effects of analgesic efficacy of the agonist-antagonist opioids.Drug Intell Clin Pharm. 1983;17(6):411-417.

161. Gear R, Becerra L, Upadhyay J, et al. Pain facilitation brain regions activated by nalbuphine are revealed by pharmacological fMRI.PLoS ONE. 2013;8(1):e50169.

162. Gunion MW, Marchionne AM, Anderson CTM. Use of the mixed agonist-antagonist nalbuphine in opioid based analgesia.Acute Pain. 2004;6(1):29-39.

163. De Souza EB, Schmidt WK, Kukor MJ. Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic.J Pharmacol Exp Ther.1988;244(1):391-402.

164. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II.Psychosomatics. 2003;44(6):515-520.

165. Leavitt SB. Opioid Antagonists in Pain Management. Available at https://www.practicalpainmanagement.com/treatments/pharmacological/opioids/opioid-antagonists-pain-management. Last accessed May 17, 2017.

166. Power I. An update on analgesics.Br J Anaesth. 2011;107(1):19-24.

167. Stavitskaya L, Coop A. Most recent developments and modifications of 14-alkylamino and 14-alkoxy-4,5-epoxymorphinan derivatives.Mini Rev Med Chem. 2011;11(12):1002-1008.

168. Hamann S, Sloan PA, Witt W. Low-dose intrathecal naloxone to enhance intrathecal morphine analgesia: a case report.J Opioid Manag. 2008;4(4):251-254.

169. Arbuck D, Gharibo C, Labhsetwar S, et al. Management of opioid tolerability and related adverse effects.J Medicine. 2010;3(1): 1-10.

170. Cruciani RA, Lussier D, Miller-Saultz D, Arbuck DM. Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone.J Pain Symptom Manage. 2003;25(6):491-494.

171. Leppert W. Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction.Drug Des Dev Ther. 2015;9:2215-2231.

172. Daily Med. Entereg (Alvimopan). Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77a67dc6-35d3-48ff-9d18-292d4d442f70#Section_1. Last accessed May 17, 2017.

173. Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table.J Pain Symptom Manage. 2009;38(3):426-439.

174. Smith HS. Opioid metabolism.Mayo Clin Proc. 2009;84(7):613-624.

175. Tennant F. Making practical sense of cytochrome P450.Pract Pain Manag. 2011;10:4.

176. Samer CF, Daali Y, Wagner M, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.Br J Pharmacol. 2010;160(4):919-930.

177. College of Physicians and Surgeons of British Columbia. Recommendations for the Use of Methadone for Pain. Available at https://www.cpsbc.ca/files/pdf/Methadone-Program-Recommendations-for-the-Use-of-Methadone-for-Pain-PUBLIC.pdf. Last accessed May 17, 2017.

178. Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society.J Pain. 2014;15(4):321-337.

179. Schmidt P. Metabolism of Tapentadol: The Data to Date. Available at http://www.painmed.org/2016posters/abstract-214. Last accessed May 17, 2017.

180. Zelcer S, Kolesnikov Y, Kovalyshyn I, Pasternak DA, Pasternak GW. Selective potentiation of opioid analgesia by nonsteroidal anti-inflammatory drugs.Brain Res. 2005;1040(1-2):151-156.

181. U.S. Food and Drug Administration. Extended-Release (ER) and Long-Acting (LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS). Available at https://www.accessdata.fda.gov/drugsatfda_docs/rems/ERLA_opioids_2015.06.26_REMS_document.pdf. Last accessed May 17, 2017.

182. Federation of State Medical Boards. Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain. Available at http://www.fsmb.org/Media/Default/PDF/FSMB/Advocacy/pain_policy_july2013.pdf. Last accessed May 17, 2017.

183. Moulin DE, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.Pain Res Manag. 2014;19(6):328-335.

184. Brooks A, Kominek C, Pham TC, Fudin J. Exploring the use of chronic opioid therapy for chronic pain: when, how, and for whom?Med Clin N Am. 2016;100(1):81-102.

185. Häuser W, Bock F, Engeser P, et al. Clinical practice guideline: long-term opioid use in noncancer pain.Dtsch Arztebl Int. 2014;111(43):732-740.

186. American Geriatric Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons.J Am Geriatr Soc. 2009;57(8):1331-1346.

187. Lynch T. Management of drug-drug interactions: considerations for special populations: focus on opioid use in the elderly and long term care.Am J Manag Care. 2011;17(Suppl 11):S293-S298.

188. British Geriatrics Society. Guidance on the management of pain in older people.Age Ageing. 2013;42(Suppl 1):i1-i57.

189. Budnitz D, Pollock D, Weidenbach K, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events.JAMA. 2006;296(15):1858-1866.

190. Smith HS, Peppin JF. Toward a systematic approach to opioid rotation.J Pain Res. 2014;7:589-608.

191. Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients.Drugs Aging. 2010;27(5):417-433.

192. Kapur BM, Lala PK, Shaw JL. Pharmacogenetics of chronic pain management.Clin Biochem. 2014;47(13-14):1169-1187.

193. Ting S, Schug S. The pharmacogenomics of pain management: prospects for personalized medicine.J Pain Res. 2016;9:49-56.

194. Trescot AM. Genetic testing in pain medicine.Pain Medicine News. 2013;11:1-9.

195. Jannetto PJ, Bratanow NC. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management.Pharmacogenomics. 2009;10(7):1157-1167.

196. Vuilleumier PH, Stamer UM, Landau R. Pharmacogenomic considerations in opioid analgesia.Pharmacogenomics Pers Med. 2012;5:73-87.

197. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.Clin Pharmacol Ther. 2014;95(4):376-382.

198. Olesen AE, Sato H, Nielsen LM, et al. The genetic influences on oxycodone response characteristics in human experimental pain.Fundam Clin Pharmacol. 2015;29(4):417-425.

199. Trescot AM, Faynboym S. A review of the role of genetic testing in pain medicine.Pain Physician. 2014;17(5):425-445.

200. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions.Pain. 1990;43(3):273-286.

201. U.S. Food and Drug Administration. Transmucosal Immediate-Release Fentanyl (TIRF) Products. Available at https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=RemsDetails.page&REMS=60. Last accessed May 17, 2017.

202. American Society of Addiction Medicine. Definitions Related to the Use of Opioids for the Treatment of Pain. Available at http://www.asam.org/advocacy/find-a-policy-statement/view-policy-statement/public-policy-statements/2011/12/15/definitions-related-to-the-use-of-opioids-for-the-treatment-of-pain-consensus-statement. Last accessed May 17, 2017.

203. Endo Pharmaceuticals, Inc. Products Covered Under the ER/LA Opioid Analgesics REMS Program. Available at http://www.er-la-opioidrems.com/IwgUI/rems/products.action. Last accessed May 17, 2017.

204. Aquina CT, Marques-Baptista A, Bridgeman P, Merlin MA. OxyContin abuse and overdose.Postgrad Med. 2009;121(2):163-167.

205. Jayawant SS, Balkrishnan R. The controversy surrounding OxyContin abuse: issues and solutions.Ther Clin Risk Manag. 2005;1(2):77-82.

206. Rauck RL. What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review.Pain Pract. 2009;9(6):468-479.

207. McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia.Am J Ther. 2001;8(3):181-186.

208. Gourlay GK. Sustained relief of chronic pain: pharmacokinetics of sustained release morphine.Clin Pharmacokinet. 1998;35(3): 173-190.

209. Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs.Mayo Clin Proc. 2009;84(7):602-612.

210. Beaulieu AD, Peloso P, Bensen W, et al. A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain.Clin Ther.2007;29(1):49-60.

211. Hagen NA, Thirlwell M, Eisenhoffer J, Quigley P, Harsanyi Z, Darke A. Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain.J Pain Symptom Manage. 2005;29(1):80-90.

212. Flöter T, Koch EMW. Comparison of two oral morphine formulations for chronic severe pain of malignant and not-malignant origin.Clin Drug Investig. 1997;14:183-191.

213. Kaplan R, Parris WC, Citron ML, et al. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain.J Clin Oncol. 1998;16(10):3230-3237.

214. Klepstad P, Kaasa S, Jystad A, Hval B, Borchgrevink PC. Immediate- or sustained-release morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial.Pain. 2003;101(1-2):193-198.

215. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial.J Rheumatol. 1999;26(4):862-869.

216. Caldwell JR, Rapoport RJ, Davis JC, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial.J Pain Symptom Manage. 2002;23(4):278-291.

217. Purdue. About Oxycontin. Available at http://www.purduepharma.com/healthcare-professionals/products/oxycontin. Last accessed May 17, 2017.

218. Ackerman SJ, Mordin M, Reblando J, et al. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patient with chronic nonmalignant pain.J Manag Care Pharm. 2003;9(3):223-231.

219. Marcus DA, Glick RM. Sustained-release oxycodone dosing survey of chronic pain patients.Clin J Pain. 2004;20(5):363-366.

220. Gallagher RM, Welz-Bosna M, Gammaitoni A. Assessment of dosing frequency of sustained-release opioid preparations in patients with chronic nonmalignant pain.Pain Med. 2007;8(1):71-74.

221. Farrar JT. Point of view.Clin J Pain. 2004;20(5):367.

222. U.S. Food and Drug Administration.Approved Drug Products with Therapeutic Equivalence Evaluations. 37th ed. Rockville, MD: U.S. Dept. of Health and Human Services; 2017.

223. Fine PG, Portenoy RK. Establishing "best practices" for opioid rotation: conclusions of an expert panel.J Pain Symptom Manage. 2009;38(3):418-425.

224. Pasternak GW. Molecular insights into mu opioid pharmacology: from the clinic to the bench.Clin J Pain. 2010;26(Suppl 10):S3-S9.

225. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part2—guidance.Pain Physician. 2012;15(3 Suppl):S67-S116.

226. Webster LR, Fine PG. Overdose deaths demand a new paradigm for opioid rotation.Pain Med. 2012;13(4):571-574.

227. Farrell SE. Acetaminophen Toxicity. Available at http://emedicine.medscape.com/article/820200-overview. Last accessed May 17, 2017.

228. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes.Pain. 1999;82(3):263-274.

229. Portenoy RK, Bennett DB, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain.J Pain. 2006;7(8):583-591.

230. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice.Palliat Med. 2001;15(3):243-246.

231. Smith HS. Considerations in selecting rapid-onset opioids for the management of breakthrough pain.J Pain Res.2013;6:189-200.

232. Silverman SM. Opioid-induced hyperalgesia: clinical implications for the pain practitioner.Pain Physician. 2009;12(3):679-684.

233. DuPen A, Shen D, Ersek M. Mechanisms of opioid-induced tolerance and hyperalgesia.Pain Manag Nurs. 2007;8(3):113-121.

234. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia.Pain Physician. 2011;14(2):145-161.

235. Pierce AM, Brahm NC. Opiates and psychotropics: pharmacokinetics for practitioners.Current Psychiatry. 2011;10(6):83-87.

236. Pasternak GW, Kolesnikov YA, Babey AM. Perspectives on theN-methyl-D-aspartate nitric oxide cascade and opioid tolerance.Neuropsychopharmacology. 1995;13(4):309-313.

237. Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801.Science. 1991;251(4989):85-87.

238. Kolesnikov YA, Pick CG, Ciszewska G, Pastermak GW. Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor.Proc Natl Acad Sci U S A. 1993;90(11):5162-5166.

239. Tompkins DA, Campbell CM. Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon?Curr Pain Headache Rep. 2011;15(2):129-136.

240. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward.Scientific World Journal. 2007;7:98-111.

241. Ossipov MH, Lai J, King T, Vanderah TW, Porreca F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure.Biopolymers. 2005;80(2-3):319-324.

242. Burns LH. Ultra-Low-Dose Opioid Antagonists Enhance Opioid Analgesia While Reducing Tolerance, Dependence and Addictive Properties. Available at http://www.paintrials.com/publications/capasso8.pdf. Last accessed May 17, 2017.

243. Tennant F. Hormone abnormalities in patients with severe and chronic pain who fail standard treatments.Postgrad Med. 2015;127(1):1-4.

244. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain.Cochrane Database Syst Rev. 2010;(1):CD006605.

245. Broekmans S, Dobbels F, Milisen K, Morlion B, Vanderschueren S. Determinants of medication underuse and medication overuse in patients with chronic non-malignant pain: a multicenter study.Int J Nurs Stud. 2010;47(11):1408-1417.

246. Leider HL, Dhaliwal J, Davis EJ, Kulakodlu M, Buikema AR. Healthcare costs and nonadherence among chronic opioid users.Am J Manag Care. 2011;17(1):32-40.

247. Meghani SH, Knafl GJ. Patterns of analgesic adherence predict health care utilization among outpatients with cancer pain.Patient Prefer Adherence. 2016;10:81-98.

248. Graziottin A, Gardner-Nix J, Stumpf M, Berliner MN. Opioids: how to improve compliance and adherence.Pain Pract. 2011;11(6):574-581.

249. Benyamin R, Trescot A, Datta S, et al. Opioid complications and side effects.Pain Physician. 2008;11(Suppl 2):S105-S120.

250. Cohen KR, Frank J, Salbu RL, Israel I. Pruritus in the elderly: clinical approaches to the improvement of quality of life.P T.2012;37(4):227-237.

251. Ganesh A, Maxwell LG. Pathophysiology and management of opioid-induced pruritus.Drugs. 2007;67(16):2323-2333.

252. Leppert W. The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities.Contemp Oncol (Pozn). 2012;16(2):125-131.

253. Anisman D. Chronic Pain Management and the Use of Opiate Medications: The CDC Guideline and Beyond. Available at https://www.acponline.org/system/files/documents/about_acp/chapters/ut/17mtg/anisman.pdf. Last accessed May 17, 2017.

254. Jarzyna D, Jungquist CR, Pasero C, et al. American Society for Pain Management nursing guidelines on monitoring for opioid-induced sedation and respiratory depression.Pain Manag Nurs. 2011;12(3):118-145.

255. Gallagher R. Killing the symptom without killing the patient.Can Fam Physician. 2010;56(6):544-547.

256. Iqbal MM, Basil MJ, Kaplan J, Iqbal MT. Overview of serotonin syndrome.Ann Clinical Psychiatry. 2012;24(4):310-318.

257. Takeshita J, Litzinger M. Serotonin syndrome associated with tramadol.Prim Care Companion J Clin Psychiatry. 2009;11(5):273.

258. Meine TJ, Roe MT, Chen AY, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative.Am Heart J. 2005;149(6):1043-1049.

259. Maremmani AGI, Rovai L, Rugani F, Bacciardi S, Dell'Osso L, Maremmani I. Substance abuse and psychosis: the strange case of opioids.Eur Rev Med Pharmacol Sci. 2014;18(3):287-302.

260. Lee MC, Wanigasekera V, Tracey I. Imaging opioid analgesia in the human brain and its potential relevance for understanding opioid use in chronic pain.Neuropharmacology. 2014;84:123-130.

261. Liang X, Liu RL, Chen C, Ji F, Li T. Opioid system modulates the immune function: a review.Transl Perioper Pain Med. 2016;1(1): 5-13.

262. Sacerdote P. Opioid-induced immunosuppression.Curr Opin Support Palliat Care. 2008;2(1):14-18.

263. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review.Amer J Therap. 2004;11(5): 354-365.

264. Budd K. Pain management: is opioid immunosuppression a clinical problem?Biomed Pharmacother. 2006;60(7):310-317.

265. Vuong C, Van Uum S, O'Dell L, Lutfy K, Friedman T. The effects of opioids and opioid analogues on animal and human endocrine systems.Endocr Rev. 2010;31(1):98-132.

266. Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingmüller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence.J Clin Endocrinol Metab. 2005;90(1):203-206.

267. U.S. Food and Drug Administration. FDA Requests Removal of Opana ER for Risks Related to Abuse. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562401.htm. Last accessed June 15, 2017.

Evidence-Based Practice Recommendations Citations

1. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part2—guidance.Pain Physician. 2012;15(3 Suppl):S67-S116. Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/38257. Last accessed May 26, 2017.

2. Hooten M, Thorson D, Bianco J, et al.Pain: Assessment, Non-Opioid Treatment Approaches and Opioid Management. Bloomington, MN: Institute for Clinical Systems Improvement; 2016. Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/50568. Last accessed May 26, 2017.


Copyright © 2017 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.